MediciNova, Inc. (MNOV) is a Biotechnology company in the Healthcare sector, currently trading at $1.41. It has a SharesGrow Score of 39/100, indicating a weak investment profile with 2 out of 7 criteria passed.
Valuation: MNOV trades at a trailing Price-to-Earnings (P/E) of -5.9 (S&P 500 average ~25).
Financials: revenue is $409,657, -100%/yr average growth. Net income is $12M (loss), growing at +0.5%/yr. Net profit margin is -2928.8% (negative). Gross margin is 7.6% (-92.4 pp trend).
Balance sheet: total debt is $194,331 against $42M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 8.16 (strong liquidity). Debt-to-assets is 0.4%. Total assets: $46M.
Analyst outlook: 4 / 4 analysts rate MNOV as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 30/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 0/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).
